{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Sanchez-Arago M"],"pubmed_abstract":["<h4>Background</h4>Metabolic reprogramming resulting in enhanced glycolysis is a phenotypic trait of cancer cells, which is imposed by the tumor microenvironment and is linked to the down-regulation of the catalytic subunit of the mitochondrial H+-ATPase (β-F1-ATPase). The bioenergetic signature is a protein ratio (β-F1-ATPase/GAPDH), which provides an estimate of glucose metabolism in tumors and serves as a prognostic indicator for cancer patients. Targeting energetic metabolism could be a viable alternative to conventional anticancer chemotherapies. Herein, we document that the bioenergetic signature of isogenic colon cancer cells provides a gauge to predict the cell-death response to the metabolic inhibitors, 3-bromopyruvate (3BrP) and iodoacetate (IA), and the anti-metabolite, 5-fluoro"],"journal":["Journal of translational medicine"],"pagination":["19"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3045315"],"repository":["biostudies-literature"],"pubmed_title":["The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil."],"pmcid":["PMC3045315"],"pubmed_authors":["Cuezva JM","Sanchez-Arago M"],"additional_accession":[]},"is_claimable":false,"name":"The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil.","description":"<h4>Background</h4>Metabolic reprogramming resulting in enhanced glycolysis is a phenotypic trait of cancer cells, which is imposed by the tumor microenvironment and is linked to the down-regulation of the catalytic subunit of the mitochondrial H+-ATPase (β-F1-ATPase). The bioenergetic signature is a protein ratio (β-F1-ATPase/GAPDH), which provides an estimate of glucose metabolism in tumors and serves as a prognostic indicator for cancer patients. Targeting energetic metabolism could be a viable alternative to conventional anticancer chemotherapies. Herein, we document that the bioenergetic signature of isogenic colon cancer cells provides a gauge to predict the cell-death response to the metabolic inhibitors, 3-bromopyruvate (3BrP) and iodoacetate (IA), and the anti-metabolite, 5-fluoro","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Feb","modification":"2025-04-03T22:22:32.131Z","creation":"2019-03-27T00:39:13Z"},"accession":"S-EPMC3045315","cross_references":{"pubmed":["21303518"],"doi":["10.1186/1479-5876-9-19"]}}